Stock vs Stock Comparison

Clover Health Investments, Corp. vs Abbott Laboratories

ABT wins the Tale of the Tape 8–1.

CLOV$4.62
ABT$100.68

🏆 Tale of the Tape

18
CLOVABT
-4.5%Profitability (Net Margin)14.7%
Valuation (P/E)27.7x
-20.3%Efficiency (ROIC)10.1%
2/9Health (Piotroski F)5/9
Safety (Altman Z)4.9
40.3%Growth (Rev YoY)5.7%
Risk (Sharpe 1Y)-0.98
0.75xBalance Sheet (D/E)0.64x
FCF Yield4.18%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

-0.019
252-Day Correlation
-0.056
126-Day Correlation

Low correlation — excellent diversification pair.

Fundamentals

MetricCLOVABT
Market Cap$2.4B$175.4B
P/E Ratio27.7x
Forward P/E46.2x16.6x
P/B7.15x3.35x
Dividend Yield0.03%
Beta2.420.61

Quantitative Metrics

MetricCLOVABT
DCF Fair Value$67.82
DCF Upside-32.6%
Piotroski F2/95/9
Altman Z4.89
Beneish M-1.81-2.53
FCF Yield4.18%
Net Debt/EBITDA0.1x
ROIC-20.3%10.1%
WACC8.4%
ROIC – WACC1.7pp
Gross Margin18.5%56.4%
Net Margin-4.5%14.7%
Rev Growth YoY40.3%5.7%
Sharpe (1Y)-0.98
Max Drawdown 3Y
FCF Payout Ratio56%

CLOV Price

Loading chart...

ABT Price

Loading chart...

ETF Exposure

CLOV found in:

XHS1.44%
VHT0.03%

ABT found in:

IHI16.93%
XLV2.94%
IYH2.64%
VHT2.33%
XHE1.71%
DGRW1.43%
NOBL1.34%
SDY1.07%
MGV0.75%
VIG0.69%
VFMV0.69%
SCHV0.68%
VYM0.65%
VTV0.59%
IWD0.58%
SPYV0.58%
VONV0.44%
IVV0.41%
QUS0.37%
SPLG0.37%
ESGV0.36%
ITOT0.36%
SCHX0.33%
SCHB0.30%
SPY0.27%
SPTM0.25%
VOO0.24%
URTH0.24%
VONE0.23%
VTI0.22%
ACWI0.16%
RSP0.16%
VT0.13%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

CLOV vs ABT: Head-to-Head Analysis

Clover Health Investments, Corp. (CLOV) and Abbott Laboratories (ABT) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, ABT leads 8–1 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, CLOV generates a return on invested capital (ROIC) of -20.3% compared to ABT's 10.1%. This suggests ABT is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between CLOV and ABT is -0.019, indicating low correlation, making them an effective diversification pair in a portfolio context.

CLOV appears in 2 ETFs tracked by SecuritiesDB, while ABT appears in 34 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, CLOV or ABT?

Our quantitative analysis compares CLOV and ABT across nine fundamental dimensions. ABT wins the Tale of the Tape 8–1. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are CLOV and ABT correlated?

The 252-day correlation between CLOV and ABT is -0.019. They have low correlation, offering good diversification.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.